On 15 December 2017, the Danish Parliament adopted by unanimous vote a new Act on a pilot scheme on cannabis for medicinal use (the “Cannabis Act”).
The scheme will be introduced on 1 January 2018. In anticipation of the final adoption of the Act, the Danish Medicines Agency (DMA) began in October 2017 to accept applications for authorisation to import and/or manufacture cannabis-containing substances for medicinal use. One company authorisation has been issued, and six more are pending.
The scheme primarily concerns cannabis products imported from EEA member states, and separate, parallel legislation provides for the growing of cannabis for medicinal use in Denmark.
The imported products must have been legally grown and distributed in the exporting country. Two products imported from the Netherlands were approved on 21 December 20171.
The declared purpose of the Act is to allow a four-year trial period to gather experience and possibly sufficient documentation to establish a permanent